Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455720 | 0.86 | TDP1 (0.53) | TDP1MEN1KMT2ACA2CA1 | |
| Ammonia Solution, Strong SCHEMBL27849182 | 0.84 | TDP1 (0.51) | TDP1MEN1KMT2ACA2CA1 | |
| SCHEMBL11832901 | 0.84 | TDP1 (0.51) | TDP1MEN1KMT2ACA2CA1 | |
| SCHEMBL8462480 | 0.83 | CA2 (0.43) | CA2CA1MAPK1POLB | |
| SCHEMBL1292730 | 0.82 | TDP1 (0.50) | TDP1MEN1KMT2ACA2CA1 | |
| SCHEMBL27816951 | 0.81 | TDP1 (0.38) | TDP1MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL650590 | 0.80 | TDP1 (0.45) | TDP1MEN1KMT2ACA2CA1 | |
| SCHEMBL4416132 | 0.79 | TDP1 (0.51) | TDP1MEN1KMT2ACA1L3MBTL1 | |
| SCHEMBL10137807 | 0.79 | CA2 (0.50) | TDP1CA2CA1MAPK1MAPT | |
| SCHEMBL245120 | 0.79 | CA1 (0.46) | CA2CA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1633434-A | Imidazo [1, 2-a ] pyridine derivatives | DAIICHI SEIYAKU CO (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | TDP1 2394/4885MEN1 2268/4885KMT2A 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.